Oncorena
2 known investors
Oncorena is developing orellanine as a potential treatment for metastatic renal cell carcinoma and is running a clinical trial to evaluate its safety, tolerability, and anti-tumor efficacy in patients with metastatic clear-cell or papillary renal cell carcinoma. The company operates in oncology drug development for kidney cancer patients.
BiotechHealthtech
Investors · 2
Frequently asked questions
- What does Oncorena do?
- Oncorena is developing orellanine as a potential treatment for metastatic renal cell carcinoma and is running a clinical trial to evaluate its safety, tolerability, and anti-tumor efficacy in patients with metastatic clear-cell or papillary renal cell carcinoma. The company operates in oncology drug development for kidney cancer patients.
- Who are Oncorena's investors?
- Oncorena's investors include FSG, HealthCap.